Will Pizii | Authors


Clinical Activity Is Found With Triplet Combination and ADCs in HER2-Mutant MBC

September 24, 2022

Results from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR-positive/ HER2-negative metastatic breast cancer compared with other variations and monotherapies of the 3 drugs.